Recent Updates
Recently added Catalysts
ALEC Positive Sentiment

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alector has reported its financial results for the second quarter of 2026, highlighting advancements in its Alector Brain Carrier platform. The company is focusing on various modalities, including antibodies and siRNA, with AL137 being the lead program targeting Alzheimer's disease. Progress is also noted for other candidates like AL064 and AL164.

Market Sentiment Analysis

POSITIVE FACTORS

  • Advancing the Alector Brain Carrier platform across multiple modalities.
  • AL137 is progressing as a lead program for Alzheimer's disease.
  • Continued progress on other ABC-enabled therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~9 mo
Medium dilution risk
Lead asset
AL001
Phase 2 · Frontotemporal Dementia

Full Press Release Details

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC -enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD). Continued progress across AL064/AL164 ( ABC -enabled Tau siRNA for

Frequently Asked Questions

What were Alector's financial results for Q2 2026?

Alector reported its financial results for the second quarter of 2026, showcasing advancements in its product pipeline.

What is the focus of Alector's lead program AL137?

AL137 is Alector's lead anti-amyloid beta antibody program targeting Alzheimer's disease.

What other programs are advancing at Alector?

Alector is also progressing with AL064 and AL164, which are ABC-enabled Tau siRNA therapies.

ShareAdd on Google
Tags: ALEC Viatris Investor Conferences Healthcare Alector AL137 Alzheimer's disease financial results biopharma
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$207M liquidity · $17M/mo burn
~9 mo
Medium dilution risk
Lead asset
AL001Phase 2
Frontotemporal Dementia →